Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Int Ophthalmol ; 42(10): 3221-3228, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-35546379

RESUMO

PURPOSE: To determine the prevalence of adenoviral conjunctivitis in Turkish ophthalmologists, to provide an overview of the treatment and prophylaxis of adenoviral conjunctivitis, and to analyze the data in the context of evidence-based treatment recommendations. METHODS: An online questionnaire consisting of 20 multiple-choice questions about the characteristics of the respondents, the individual adenoviral conjunctivitis history of the ophthalmologists, their practice's approaches, and prescription preferences were emailed to Turkish ophthalmologists. RESULTS: The survey was emailed to 500 ophthalmologists; 45% of them returned the questionnaire. According to the responses, the history of adenoviral conjunctivitis infections was positive in 46.7% (n: 120), recurrent attack prevalence was 16.2% in ophthalmologists. Lubricants (67.6%) are the most preferred first-line treatment options for adenoviral conjunctivitis, followed by povidone-iodine (59.6%), topical antibiotics (51.1%), topical antivirals (29.3%), topical corticosteroids (26.7%), and topical nonsteroidal anti-inflammatory agents (19.6%). A total of 98.2% preferred to dismiss infected patients. The preferred prophylaxis options were frequent hand washing/use of gloves (97.8%), disinfection of medical devices (95.1%), isolation of infected patients (79.1%), hand hygiene with gemicides (58.7%). The percentage of single-dose eye drop selection was 46.2. CONCLUSIONS: The findings of this survey showed that most Turkish ophthalmologists generally follow international guidelines for the treatment of adenoviral conjunctivitis. The treatment algorithm is still controversial, so ophthalmologists should be aware of treatment guideline updates in line with evidence-based recommendations. Having sufficient knowledge of the basic characteristics of viruses is important to control the spread of the disease.


Assuntos
Infecções por Adenoviridae , Conjuntivite Viral , Conjuntivite , Oftalmologistas , Infecções por Adenoviridae/tratamento farmacológico , Corticosteroides/uso terapêutico , Antibacterianos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Antivirais/uso terapêutico , Conjuntivite/tratamento farmacológico , Conjuntivite Viral/tratamento farmacológico , Conjuntivite Viral/epidemiologia , Conjuntivite Viral/prevenção & controle , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Lubrificantes/uso terapêutico , Soluções Oftálmicas/uso terapêutico , Povidona-Iodo/uso terapêutico , Inquéritos e Questionários
2.
Front Immunol ; 12: 638575, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33968030

RESUMO

Metformin is not only the first-line medication for the treatment of type 2 diabetes, but it is also effective as an anti-inflammatory, anti-oxidative and anti-tumor agent. However, the effect of metformin during viral hepatitis remains elusive. Using an adenovirus (Ad)-induced viral hepatitis mouse model, we found that metformin treatment significantly attenuated liver injury, with reduced serum aspartate transaminase (AST) and alanine transaminase (ALT) levels and liver histological changes, presumably via decreased effector T cell responses. We then demonstrated that metformin reduced mTORC1 activity in T cells from infected mice, as evidenced by decreased phosphorylation of ribosome protein S6 (p-S6). The inhibitory effects on the mTORC1 signaling by metformin was dependent on the tuberous sclerosis complex 1 (TSC1). Mechanistically, metformin treatment modulated the phosphorylation of dynamin-related protein 1 (Drp-1) and mitochondrial fission 1 protein (FIS1), resulting in increased mass in effector T cells. Moreover, metformin treatment promoted mitochondrial superoxide production, which can inhibit excessive T cell activation in viral hepatitis. Together, our results revealed a protective role and therapeutic potential of metformin against liver injury in acute viral hepatitis via modulating effector T cell activation via regulating the mTORC1 pathway and mitochondrial functions.


Assuntos
Infecções por Adenoviridae/tratamento farmacológico , Adenoviridae/fisiologia , Hepatite Viral Animal/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Fígado/patologia , Metformina/uso terapêutico , Mitocôndrias/metabolismo , Infecções por Adenoviridae/imunologia , Animais , Células Cultivadas , Modelos Animais de Doenças , Metabolismo Energético , Feminino , Hepatite Viral Animal/imunologia , Humanos , Fígado/efeitos dos fármacos , Ativação Linfocitária , Alvo Mecanístico do Complexo 1 de Rapamicina/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Proteína 1 do Complexo Esclerose Tuberosa/metabolismo
3.
Ocul Surf ; 17(4): 828-832, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31401340

RESUMO

PURPOSE: To report safety and tolerability of a one-time administration of ophthalmic 5% povidone-iodine (5% PVP-I) in a double-masked randomized trial for the treatment of adenoviral conjunctivitis (Ad-Cs). METHODS: Of 212 participants screened, 56 eligible participants with red eye symptoms ≤4 days and a positive adenoviral rapid immunoassay were randomized to a one-time administration of ophthalmic 5% PVP-I or preservative free artificial tears (AT). Safety was assessed by corneal fluorescein staining (baseline, immediate post-administration and Day 1) and visual acuity (VA) (baseline and Day 1). Tolerability was assessed using participant-rated overall ocular discomfort (baseline, immediately post-administration and on Day 1. RESULTS: In the 5% PVP-I group, corneal staining increased immediately post-administration but returned to baseline levels by Day 1. There was no change in VA between baseline and Day 1 in either 5% PVP-I or AT groups (p = 0.87). In the 5% PVP-I group, there was no change in participant-rated overall discomfort immediately post-administration (p = 0.78) or on day 1 (p = 0.10) compared to baseline. In the AT group, participant-rated overall discomfort was lower immediately post-administration but returned to baseline levels by Day 1. One adverse event was reported in the 5% PVP-I group on Day 1-2 that was classified as not related to treatment. CONCLUSION: These results suggest ophthalmic 5% PVP-I used as a one-time treatment is safe and well tolerated by patients with Ad-Cs.


Assuntos
Infecções por Adenoviridae/tratamento farmacológico , Conjuntivite/tratamento farmacológico , Infecções Oculares Virais/tratamento farmacológico , Lubrificantes Oftálmicos , Povidona-Iodo/administração & dosagem , Acuidade Visual , Adulto , Conjuntivite/virologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Esquema de Medicação , Feminino , Seguimentos , Humanos , Masculino , Estudos Retrospectivos , Resultado do Tratamento
4.
PLoS One ; 13(10): e0200043, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30332435

RESUMO

Infection of immunocompromised individuals with normally benign opportunistic viruses is a major health burden globally. Infections with viruses such as Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), Kaposi's sarcoma virus (KSHV), adenoviruses (AdV), BK virus (BKPyV), John Cunningham virus (JCPyV), and human papillomavirus (HPV) are significant concerns for the immunocompromised, including when these viruses exist as a co-infection with human immunodeficiency virus (HIV). These viral infections are more complicated in patients with a weakened immune system, and often manifest as malignancies resulting in significant morbidity and mortality. Vaccination is not an attractive option for these immune compromised individuals due to defects in their adaptive immune response. Verdinexor is part of a novel class of small molecules known as SINE (Selective Inhibitor of Nuclear Export) compounds. These small molecules demonstrate specificity for the nuclear export protein XPO1, to which they bind and block function, resulting in sequestration of XPO1-dependent proteins in the nucleus of the cell. In antiviral screening, verdinexor demonstrated varying levels of efficacy against all of the aforementioned viruses including previously with HIV. Studies by other labs have discussed likely mechanisms of action for verdinexor (ie. XPO1-dependence) against each virus. GLP toxicology studies suggest that anti-viral activity can be achieved at a tolerable dose range, based on the safety profile of a previous phase 1 clinical trial of verdinexor in healthy human volunteers. Taken together, these results indicate verdinexor has the potential to be a broad spectrum antiviral for immunocompromised subjects for which vaccination is a poor option.


Assuntos
Acrilamidas/farmacologia , Hidrazinas/farmacologia , Hospedeiro Imunocomprometido/efeitos dos fármacos , Carioferinas/antagonistas & inibidores , Receptores Citoplasmáticos e Nucleares/antagonistas & inibidores , Viroses/tratamento farmacológico , Infecções por Adenoviridae/tratamento farmacológico , Animais , Linhagem Celular Tumoral , Infecções por Citomegalovirus/tratamento farmacológico , Avaliação Pré-Clínica de Medicamentos , Infecções por Vírus Epstein-Barr/tratamento farmacológico , Fibroblastos/virologia , Cobaias , Células HEK293 , Infecções por HIV/complicações , Células HeLa , Humanos , Camundongos , Infecções por Papillomavirus/tratamento farmacológico , Infecções por Polyomavirus/tratamento farmacológico , Reprodutibilidade dos Testes , Sarcoma de Kaposi/tratamento farmacológico , Infecções Tumorais por Vírus/tratamento farmacológico , Viroses/complicações , Proteína Exportina 1
5.
Microbiol Immunol ; 58(5): 303-6, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24580367

RESUMO

Adenovirus 36 (Ad36) is known to be associated with human obesity and to trigger inflammation in murine models. However, to date no clinical drugs for treating virus-induced obesity have been developed. Therefore, in this study, the anti-obesity and anti-inflammation effects of mulberry extract on Ad36 were evaluated in mice. The mulberry extract-fed group showed a reduction in total body weight and in epidermal fat pads. A combination of various mulberry components (1-deoxynojirimycin, kuromanin chloride and resveratrol) and a mulberry extract prevented viral replication by 50% and 70%, respectively, compared with an untreated Ad36-infected group. Moreover, the extract decreased both concentrations of proinflammatory cytokines, such as MCP-1 and TNF-α, and the numbers of infiltrating immune cells and macrophages in epidermal fat pads. In conclusion, dietary mulberry extract might offer an avenue for the development of therapeutic approaches for treating or preventing virus-induced obesity and inflammation-related metabolic diseases.


Assuntos
Infecções por Adenoviridae/tratamento farmacológico , Adenovírus Humanos/efeitos dos fármacos , Antivirais/uso terapêutico , Morus/química , Obesidade/prevenção & controle , Extratos Vegetais/uso terapêutico , Infecções por Adenoviridae/complicações , Adenovírus Humanos/fisiologia , Animais , Antivirais/isolamento & purificação , Citocinas/metabolismo , Modelos Animais de Doenças , Inflamação/prevenção & controle , Leucócitos/imunologia , Camundongos , Extratos Vegetais/isolamento & purificação , Pele/patologia , Replicação Viral/efeitos dos fármacos
6.
J Pharm Pharmacol ; 63(5): 688-94, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21492171

RESUMO

OBJECTIVES: Astragaloside IV, purified from the Chinese medical herb Astragalus membranaceus (Fisch) Bge and Astragalus caspicus Bieb, is an important natural product with multiple pharmacological actions. This study investigated the anti-ADVs effect of astragaloside IV on HAdV-3 (human adenovirus type 3) in A549 cell. METHODS: CPE, MTT, quantitative real-time PCR (qPCR), flow cytometry (FCM) and Western blot were apply to detect the cytotoxicity, the inhibition and the mechanisms of astragaloside IV on HAdV-3. KEY FINDINGS: TC(0 ) of astragaloside IV was 116.8 µm, the virus inhibition rate from 15.98% to 65.68% positively was correlated with the concentration of astragaloside IV from 1.25 µm to 80 µm, IC50 (the medium inhibitory concentration) was 23.85 µm, LC50 (lethal dose 50% concentration) was 865.26 µm and the TI (therapeutic index) was 36.28. qPCR result showed astragaloside IV inhibited the replication of HAdV-3. Flow FCM analysis demonstrated that the anti-HAdV-3 effect was associated with apoptosis. Astragaloside IV was further detected to reduce the protein expressions of Bax and Caspase-3 and increasing the protein expressions of Bcl-2 using western blotting, which improved the anti-apoptosis mechanism of astragaloside IV on HAdV-3. CONCLUSIONS: Our findings suggested that astragaloside IV possessed anti-HAdV-3 capabilities and the underlying mechanisms might involve inhibiting HAdV-3 replication and HAdV-3-induced apoptosis.


Assuntos
Infecções por Adenoviridae/tratamento farmacológico , Adenoviridae/efeitos dos fármacos , Antivirais/farmacologia , Apoptose/efeitos dos fármacos , Astragalus propinquus/química , Fitoterapia , Saponinas/farmacologia , Triterpenos/farmacologia , Adenoviridae/patogenicidade , Adenoviridae/fisiologia , Infecções por Adenoviridae/metabolismo , Caspase 3/metabolismo , Linhagem Celular , Humanos , Concentração Inibidora 50 , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Replicação Viral/efeitos dos fármacos , Proteína X Associada a bcl-2/metabolismo
7.
Biol Pharm Bull ; 34(2): 197-202, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21415527

RESUMO

Radix Lithosperm eyrthrorhizon is a common prescription compound in traditional Chinese medicine. Shikonin is a major component of Radix Lithospermi and has various biological activities. We have investigated the inhibitory effect of shikonin on the growth of adenovirus type 3 (AdV3) in vitro. The antiviral function of shikonin against AdV3 and its virus inhibition ratio were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method (MTT). The expression of hexon protein in AdV3 was determined by immunofluorescence assay using laser scanning confocal microscopy (LSCM) and Western blot analysis. In addition, the rate of apoptosis in cells infected by AdV3 was determined by flow cytometry. Shikonin (0.0156-1 µM) inhibited growth of AdV3 in a concentration-dependent manner with a virus inhibition rate of 23.8-69.1%. Expression of hexon protein in AdV3 was higher in the virus control group than in the shikonin-treated groups as determined by immunofluorescence assay and Western blotting (p<0.05). The rate of shikonin-treated HeLa cell apoptosis had a statistically significant decrease with increasing concentration of drug (p<0.05). Our data demonstrate that shikonin possesses anti-AdV3 capabilities and that the potential antiviral mechanism might involve inhibiting the degree of apoptosis and hexon protein expression of AdV.


Assuntos
Infecções por Adenoviridae/tratamento farmacológico , Adenoviridae/efeitos dos fármacos , Antivirais/farmacologia , Proteínas do Capsídeo/metabolismo , Medicamentos de Ervas Chinesas/farmacologia , Lithospermum/química , Naftoquinonas/farmacologia , Adenoviridae/crescimento & desenvolvimento , Antivirais/uso terapêutico , Apoptose/efeitos dos fármacos , Relação Dose-Resposta a Droga , Medicamentos de Ervas Chinesas/uso terapêutico , Células HeLa , Humanos , Naftoquinonas/uso terapêutico , Fitoterapia , Raízes de Plantas
8.
J Appl Microbiol ; 99(6): 1346-55, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16313407

RESUMO

AIMS: Medicinal plants are increasingly being projected as suitable alternative sources of antiviral agents. The development of a suitable in vitro pharmacodynamic screening technique could contribute to rapid identification of potential bioactive plants and also to the standardization and/or pharmacokinetic-pharmacodynamic profiling of the bioactive components. METHODS AND RESULTS: Recombinant viral vectors (lentiviral, retroviral and adenoviral) transferring the firefly luciferase gene were constructed and the inhibition of viral vector infectivity by various concentrations of plant extracts was evaluated in HeLa or Hep2 cells by measuring the changes in luciferase activity. Cytotoxicity of the extracts was evaluated in parallel on HeLa or Hep2 cells stably expressing luciferase. Amongst the 15 extracts screened, only the methanol (ME) and the ethyl acetate (ET) fractions of the lichen, Ramalina farinacea specifically reduced lentiviral and adenoviral infectivity in a dose-dependent manner. Further, chromatographic fractionation of ET into four fractions (ET1-ET4) revealed only ET4 to be selectively antiviral with an IC50 in the 20 microg ml(-1) range. Preliminary mechanistic studies based on the addition of the extracts at different time points in the viral infection cycle (kinetic studies) revealed that the inhibitory activity was highest if extract and vectors were preincubated prior to infection, suggesting that early steps in the lentiviral or adenoviral replication cycle could be the major target of ET4. Inhibition of wild-type HIV-1 was also observed at a 10-fold lower concentration of the extract. CONCLUSIONS: The vector-based assay is a suitable in vitro pharmacodynamic evaluation technique for antiviral medicinal plants. The technique has successfully demonstrated the presence of antiviral principles in R. farinacea. SIGNIFICANCE AND IMPACT OF STUDY: Potential anti-HIV medicinal plants could rapidly be evaluated with the reported vector-based technique. The lichen, R. farinacea could represent a lead source of antiviral substances and is thus worthy of further studies.


Assuntos
Antivirais/uso terapêutico , Vetores Genéticos/administração & dosagem , Medicinas Tradicionais Africanas , Extratos Vegetais/uso terapêutico , Plantas Medicinais , Infecções por Adenoviridae/tratamento farmacológico , Adenovírus Humanos/genética , Adenovírus Humanos/fisiologia , Bioensaio , Linhagem Celular Tumoral , Engenharia Genética , Vetores Genéticos/genética , HIV/genética , HIV/fisiologia , Infecções por HIV/tratamento farmacológico , Células HeLa , Humanos , Luciferases/genética , Medições Luminescentes , Nigéria , Retroviridae/genética , Retroviridae/fisiologia
9.
Antiviral Res ; 61(1): 63-6, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14670595

RESUMO

To determine the antiviral effects of compounds against ocular adenovirus (AdV) infection, we established an animal model of AdV infection in cotton rat eyes. Cotton rat eyes were inoculated intrastromally and topically with four AdV serotypes 4, 5, 8, and 37, and treated topically with 1% HPMPC (cidofovir) eye drops twice a day. The infected corneas were extracted and homogenized, and virus titers in the cornea specimens were determined by a plaque assay. The virus titer in AdV type 5-inoculated eyes peaked on days 0 through 3 after inoculation and virus shedding was detected for 18.0+/-2.8 days. AdV 5 antigen in the infected corneas was demonstrated in the corneal epithelial cells by immunofluorescence stain. However, for AdV serotypes 4, 8, and 37, no evidence of continued virus replication in cotton rat eyes was noted. Specimens from cidofovir-treated eyes infected with AdV 5 demonstrated a statistically significant reduction in the mean virus titer (days 3-15) (P=0.028) and virus shedding duration (P=0.0014), as compared with those of the control group.


Assuntos
Infecções por Adenoviridae/tratamento farmacológico , Adenovírus Humanos/efeitos dos fármacos , Antivirais/uso terapêutico , Citosina/análogos & derivados , Citosina/uso terapêutico , Infecções Oculares Virais/tratamento farmacológico , Organofosfonatos , Compostos Organofosforados/uso terapêutico , Infecções por Adenoviridae/virologia , Adenovírus Humanos/crescimento & desenvolvimento , Administração Tópica , Animais , Antígenos Virais/análise , Antivirais/farmacologia , Cidofovir , Conjuntivite Viral/tratamento farmacológico , Córnea/virologia , Citosina/administração & dosagem , Citosina/farmacologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Feminino , Compostos Organofosforados/administração & dosagem , Compostos Organofosforados/farmacologia , Ratos , Sigmodontinae , Ensaio de Placa Viral , Replicação Viral/efeitos dos fármacos , Eliminação de Partículas Virais/efeitos dos fármacos
10.
Am J Chin Med ; 31(6): 897-905, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14992542

RESUMO

In an effort to find new antiviral agents from natural products, hot water extracts of eight traditionally used medicinal plants in Taiwan were investigated in vitro for their activities against adenoviruses (ADV) and herpes simplex viruses (HSV). Results demonstrated that all extracts exhibited antiviral activity with different degrees of potency. Only two extracts were active in suppressing both HSV and ADV infections. Three extracts inhibited only ADV infection whereas one extract blocked only HSV infection. These results suggested that the aforementioned medicinal plants merit further investigation.


Assuntos
Infecções por Adenoviridae/tratamento farmacológico , Antivirais/farmacologia , Medicamentos de Ervas Chinesas/farmacologia , Herpes Simples/tratamento farmacológico , Antivirais/toxicidade , Carcinoma Basocelular , Linhagem Celular Tumoral , Medicamentos de Ervas Chinesas/toxicidade , Humanos , Técnicas In Vitro , Neoplasias Cutâneas , Taiwan , Água
11.
Vopr Virusol ; 31(2): 225-8, 1986.
Artigo em Russo | MEDLINE | ID: mdl-3014753

RESUMO

A certain role in the outcome of virus infection of cells was assumed to belong to cell membrane lipids peroxidation. The influence of known inhibitors of lipid peroxidation, beta-naphthol and ionol, on HeLa cells infection with human adenovirus type 2 was studied. These antioxidants in certain concentrations were found to be capable of effectively inhibiting virus infection of HeLa cell cultures. At the same time, beyond these concentration levels these antioxidants did not inhibit but stimulated virus infection of HeLa cell cultures. It is concluded that inhibition of virus infection of cells by antioxidants in moderate concentrations is due to their blocking of membrane lipids peroxidation. The opposite effect of antioxidants in much higher or lower concentrations may be due to their membranotropic effect which enhances the development of virus infection. The results of the study attest to the possible use of antioxidants in appropriate concentrations for control of virus infection.


Assuntos
Infecções por Adenoviridae/tratamento farmacológico , Infecções por Adenovirus Humanos/tratamento farmacológico , Antioxidantes/uso terapêutico , Células HeLa/efeitos dos fármacos , Infecções por Adenovirus Humanos/metabolismo , Hidroxitolueno Butilado/uso terapêutico , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Células HeLa/metabolismo , Humanos , Peróxidos Lipídicos/metabolismo , Lipídeos de Membrana/metabolismo , Naftóis/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA